Skip to main content
TipRanks
Go Ultimate75% OFF

Artemis Medicare Services Ltd. (ARTEMISMED) AI Stock Analysis

2 Followers
IN:ARTEMISMED

Artemis Medicare Services Ltd.

(NSE:ARTEMISMED)

Select Model
Rating:70Outperform
Price Target:INR 353.00â–²(9.88% Upside)
Action:reiterated
Date:09/26/26

The score is driven primarily by strong financial performance (growth, higher margins, and improved leverage) and supportive technical strength (clear uptrend with positive momentum). These positives are partially offset by weaker cash-flow consistency and a demanding valuation (high P/E), despite the supportive dividend yield.

Positive Factors
Sustained Revenue GrowthThe substantial increase in revenue over several years, combined with continued growth through 2026, indicates expanding business activity rather than a single-period improvement. Sustained top-line growth can support operating scale, strengthen the company’s market position, and provide a durable base for future earnings.
Negative Factors
Volatile Free Cash FlowAlthough operating cash flow is consistently positive, the history of negative free cash flow followed by later improvement shows that cash generation after capital spending has not been consistent. Uneven conversion can constrain internally funded growth and make liquidity more dependent on sustained earnings and disciplined investment.

Artemis Medicare Services Ltd. (ARTEMISMED) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%IN:ARTEMISMED+13.85%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 50.94B
Dividend Yield
0.14%
Average Volume (3M)
44.85K
Price to Earnings (P/E)
43.3
Beta (1Y)
0.82
Revenue Growth
14.77%
EPS Growth
8.40%
Country
India
Employees
2,055
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Artemis Medicare Services Ltd. Business Overview & Revenue Model

Company Description

Artemis Medicare Services Limited engages in the management and operation of multi-specialty hospitals in India and internationally. The company provides medical and surgical intervention, and inpatient and outpatient services. It also offers billing...

Artemis Medicare Services Ltd. Financial Statement Overview

Summary

Strong multi-year revenue growth and materially improved profitability through 2026 support a solid score. Balance sheet risk has eased with much lower debt-to-equity by 2026, but cash-flow quality is the main drag due to volatile free cash flow and weaker recent cash conversion.

Income Statement

78Positive

Balance Sheet

74Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue11.50B10.81B9.37B8.79B7.37B5.53B
Gross Profit2.37B2.15B2.23B1.78B1.04B954.40M
EBITDA1.99B1.88B1.52B1.34B1.01B713.53M
Net Income1.15B1.04B826.26M491.41M385.98M318.14M
Balance Sheet
Total Assets15.98B14.29B13.57B9.72B9.05B7.10B
Cash, Cash Equivalents and Short-Term Investments2.67B2.06B3.96B612.05M509.42M276.98M
Total Debt3.24B2.62B2.90B3.20B2.86B2.01B
Total Liabilities6.02B4.88B5.14B5.17B4.97B3.48B
Stockholders Equity9.89B9.35B8.38B4.48B4.03B3.59B
Cash Flow
Free Cash Flow0321.88M524.65M363.01M-337.68M-573.20M
Operating Cash Flow01.37B1.46B1.09B1.13B515.80M
Investing Cash Flow0-1.19B-3.85B-891.04M-1.58B-1.08B
Financing Cash Flow0-265.64M2.67B-41.48M521.82M528.37M

Artemis Medicare Services Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price321.25

Price Trends

50DMA320.03Positive
100DMA305.69Positive
200DMA274.49Positive

Market Momentum

MACD-0.92Negative
RSI59.82Neutral
STOCH89.67Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARTEMISMED, the sentiment is Positive. The current price of 321.25 is above the 20-day moving average (MA) of 300.46, above the 50-day MA of 320.03, and above the 200-day MA of 274.49, indicating a bullish trend. The MACD of -0.92 indicates Negative momentum. The RSI at 59.82 is Neutral, neither overbought nor oversold. The STOCH value of 89.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ARTEMISMED.

Artemis Medicare Services Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ARTEMISMED against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:YATHARTHIN:YATHARTH80OutperformINR 102.05B53.66―0.05%50.40%24.94%
IN:KOVAIIN:KOVAI74OutperformINR 71.39B26.55―0.23%16.69%18.45%
IN:JLHLIN:JLHL72OutperformINR 93.53B50.14―0.07%16.71%-6.09%
IN:ARTEMISMEDIN:ARTEMISMED70OutperformINR 50.18B43.25―0.14%14.77%8.40%
IN:RAINBOWIN:RAINBOW61NeutralINR 131.36B44.16―0.27%22.83%15.15%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:SHALBYIN:SHALBY35UnderperformINR 13.77B34.56――7.27%774.36%

* General Sector Average

Performance Comparison

-40%-20%0%20%40%IN:ARTEMISMEDIN:JLHLIN:RAINBOWIN:SHALBYIN:YATHARTHIN:KOVAIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ARTEMISMED and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ARTEMISMEDArtemis Medicare Services Ltd.321.2550.4118.61%
IN:JLHLJupiter Life Line Hospitals Ltd.283.50-7.07-2.43%
IN:RAINBOWRainbow Childrens Medicare Limited1275.95-28.53-2.19%
IN:SHALBYShalby Ltd.124.85-98.95-44.21%
IN:YATHARTHYatharth Hospital and Trauma Care Services Limited1061.20266.5233.54%
IN:KOVAIKovai Medical Center & Hospital Ltd.6570.25515.278.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 26, 2026